El Futuro en el Tratamiento del Cáncer Renal - page 23

NK Cell–Targeted Anti–Killer Cell Ig-Like Receptor Ab. (Anti-KIR)

Lirilumab in Combination With Nivolumab or Ipilimumab

Segal NH, et al. ESMO 2016

Vvier E, et al. Data not published

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,13,14,15,16,17,18,19,20,21,22 24,25,26,27,28,29,30,31,32,33,...36